Sinocelltech Group Limited: COVID-19 trials

The registry lists 22 COVID-19 studies with Sinocelltech Group Limited as lead sponsor. 2 are open to participants now and 1 have results posted.

Phase 1 5Phase 2 17Phase 3 6No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster VaccinesNot yet recruitingNCT05933512Phase 2
• To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19Not yet recruitingNCT04709328Phase 2/3
• The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19TerminatedNCT04644185Phase 2/3Results posted
• Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023Status unknownNCT05758675
• A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy PeopleStatus unknownNCT05683561Phase 3
• A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCompletedNCT05652543Phase 2
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 YearsStatus unknownNCT05522829Phase 2
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 YearsStatus unknownNCT05345873Phase 2
• A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 YearsStatus unknownNCT05329051Phase 2
• A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster VaccinesStatus unknownNCT05323461Phase 3
• A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 YearsWithdrawnNCT05308602Phase 2
• A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 YearsActive, not recruitingNCT05308576Phase 3
• A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 VaccineWithdrawnNCT05239975Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 VaccineStatus unknownNCT05239806Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 VaccineStatus unknownNCT05238454Phase 2
• A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 VaccineStatus unknownNCT05238441Phase 2
• A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19WithdrawnNCT05156645Phase 1/2
• The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated AdultsCompletedNCT05148091Phase 1/2
• The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.Status unknownNCT05043311Phase 1/2
• The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.Status unknownNCT05043285Phase 1/2
• The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive CareStatus unknownNCT04683328Phase 2/3
• Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese SubjectsCompletedNCT04483375Phase 1